US EditionFirst Patient Treated in Myra Vision's U.S. ADAPT Clinical Study for Glaucoma
The ADAPT trial will enroll up to 70 refractory glaucoma patients to assess safety and effectiveness of the first adjustable glaucoma shunt in the U.S.
- On Jan. 26, 2026, Myra Vision announced it enrolled the first patient in the ADAPT IDE study, with Dr. David Godfrey performing the initial case at Glaucoma Associates of Texas.
- Following FDA Investigational Device Exemption approval in August 2025, Myra Vision is developing an aqueous shunt to enable safe, personalized intraocular pressure control, addressing the lack of postoperative adjustability in traditional glaucoma surgery.
- The ADAPT trial will evaluate safety and effectiveness of the Calibreye System, described as the first adjustable glaucoma shunt in the U.S., enrolling up to 70 refractory patients over 12 months.
- Myra Vision's CEO Robert Chang said enrollment is a significant accomplishment and an important step toward delivery, while advisors and Shifamed LLC, founded by Amr Salahieh, praised the U.S. trial progress.
- With glaucoma affecting 80M people worldwide, titratable glaucoma therapy like Calibreye could provide meaningful solutions for moderate-to-advanced patients needing individualized IOP control.
9 Articles
9 Articles
Gilbert Sun News
First Patient Treated in Myra Vision's U.S. ADAPT Clinical Study for Glaucoma
Initial case conducted by Dr. David Godfrey at Glaucoma Associates of TexasThe IDE study will evaluate the safety and effectiveness of the company's Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System
Medical Device Network
Verdict HospitalMyra Vision enrols first patient in trial of Calibreye glaucoma system
Myra Vision has enrolled the first patient in the ADAPT clinical trial assessing its Calibreye TGT surgical system in the US, following recent approval of its Investigational Device Exemption by the FDA.The post Myra Vision enrols first patient in trial of Calibreye glaucoma system appeared first on Medical Device Network.
First Patient Treated in Myra Vision’s U.S. ADAPT Clinical Study for Glaucoma
Initial case conducted by Dr. David Godfrey at Glaucoma Associates of Texas The IDE study will evaluate the safety and effectiveness of the company’s Calibreye Titratable Glaucoma Therapy (TGT) Surgical System CAMPBELL, Calif., Jan. 26, 2026 /PRNewswire/ — Myra Vision, a Shifamed portfolio company, today announced the first patient enrolled in its ADAPT clinical study evaluating the Calibreye TGT Surgical System in patients with glaucoma. This …
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
